Germany's Merck Swaps CAR-T Rights For Equity In Intrexon, Focusing Its R&D
Merck KGaA has rejigged a 2015 drug development deal with NASDAQ-listed Intrexon, swapping rights to potential CAR-T therapies for stock in the biology specialist.
You may also be interested in...
The new year starts with a strategic shift by Intrexon. Also, Roivant and Sumitomo Dainippon launch Sumitovant, Melinta reorganizes through Chapter 11 bankruptcy, Acorda arranges debt relief and CF PharmTech raises a $90m series E round.
As it moves away from virology, Gilead’s signs fibrosis collaboration with Scholar Rock. Novartis seeks to acquire CMDO that manufactures Kymriah, while Intrexon regains control of CAR-T program partnered with Merck KGAA. More deals from over the holiday period…
German Merck tells Scrip Mavenclad's long spell in the regulatory 'wilderness' allowed it to amass deep safety and efficacy data that should help the oral MS drug's commercial prospects.